Active substance
Isosorbide
- SFDA 11
- US FDA 67
- Health Canada 2
- US price lines 10
- NHS prices 16
- WHO EML 1
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| ISOBIDE | 40 mg | Modified-release capsule · Oral use | 20 Blister | SAR 27.30 | Generic · Prescription | RIYADH PHARMA | Valid |
| ISOBIDE | 20 mg | Modified-release capsule · Oral use | 20 Blister | SAR 18.85 | Generic · Prescription | RIYADH PHARMA | Valid |
| IMDUR 60MG DURULES | 60 mg | Tablet · Oral use | 30 Blister | SAR 25.25 | NCE · Prescription | AstraZeneca | Withdrawn by regulatory authority · Not Marketed |
| IMDUR 60MG DURULES | 60 mg | Tablet · Oral use | 100 Tablet Container | SAR 74.85 | NCE · Prescription | AstraZeneca | Withdrawn by regulatory authority · Not Marketed |
| ISOKET 0.1% AMPOULE | 0.1 % | Solution · Intravenous use | 10 Ampoule | SAR 72.45 | NCE · Prescription | SCHWARTZ PHARMA | Invalid · Not Marketed |
| ISORDIL 10 MG. TABLETS | 10 mg | Tablet · Oral use | 100 Tablet Container | SAR 16.25 | NCE · Prescription | WYETH | Withdrawn by MAH · Not Marketed |
| ISORDIL SUBLINGUAL 5 MG. TAB. | 5 mg | Tablet · Sublingual use | 100 Tablet Container | SAR 16.25 | NCE · Prescription | PFIZER | Withdrawn by MAH · Not Marketed |
| WESORBIDE 10MG TAB | 10 mg | Tablet · Oral use | 100 Tablet Container | SAR 8.80 | Generic · Prescription | WEST-WARD | Withdrawn by MAH · Not Marketed |
| WESORBIDE 2.5MG SUBLINGUAL TAB | 2.5 mg | Tablet · Sublingual use | 100 Tablet Container | SAR 5.20 | Generic · Prescription | WEST-WARD | Withdrawn by MAH · Not Marketed |
| WESORBIDE 20MG TAB | 20 mg | Tablet · Oral use | 100 Tablet Container | SAR 14.45 | Generic · Prescription | WEST-WARD | Withdrawn by MAH · Not Marketed |
| WESORBIDE 5MG S-L TAB | 5 mg | Tablet · Oral use | 100 Tablet Container | SAR 8.80 | Generic · Prescription | WEST-WARD | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
CARDIOMYOPATHY; CORONARY ARTERY DISEASE
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ISORDIL | 40MG; 5MG | tablet · oral | BAUSCH | Prescription | 9 Nov 1959 |
| ISOSORBIDE DINITRATE | 5MG | tablet · oral | PH HEALTH | Prescription | 12 Mar 1987 |
| ISOSORBIDE DINITRATE | 10MG | tablet · oral | PH HEALTH | Prescription | 12 Mar 1987 |
| ISOSORBIDE DINITRATE | 30MG | tablet · oral | PH HEALTH | Prescription | 12 Mar 1987 |
| ISOSORBIDE DINITRATE | 20MG | tablet · oral | PH HEALTH | Prescription | 2 Oct 1987 |
| ISOSORBIDE DINITRATE | 20MG; 10MG; 5MG | tablet · oral | HIKMA INTL PHARMS | Prescription | 2 Nov 1987 |
| ISOSORBIDE DINITRATE | 5MG | tablet · oral | SANDOZ | Prescription | 7 Jan 1988 |
| ISOSORBIDE DINITRATE | 10MG | tablet · oral | SANDOZ | Prescription | 7 Jan 1988 |
| ISOSORBIDE DINITRATE | 20MG | tablet · oral | SANDOZ | Prescription | 7 Apr 1988 |
| MONOKET | 20MG; 10MG | tablet · oral | OMNIVIUM PHARMS | Prescription | 30 Jun 1993 |
| ISOSORBIDE MONONITRATE | 20MG; 10MG | tablet · oral | GENUS | Prescription | 30 Oct 1998 |
| ISOSORBIDE MONONITRATE | 60MG; 30MG; 120MG | tablet, extended release · oral | CHARTWELL MOLECULAR | Prescription | 30 Oct 1998 |
| ISOSORBIDE MONONITRATE | 20MG; 10MG | tablet · oral | ANI PHARMS | Prescription | 27 Nov 1998 |
| ISOSORBIDE MONONITRATE | 30MG; 60MG; 120MG | tablet, extended release · oral | ZYDUS HLTHCARE | Prescription | 16 Mar 2000 |
| ISOSORBIDE MONONITRATE | 60MG; 30MG | tablet, extended release · oral | DEXCEL LTD | Prescription | 17 Apr 2000 |
| ISOSORBIDE MONONITRATE | 30MG | tablet, extended release · oral | TORRENT PHARMS | Prescription | 3 Jun 2011 |
| ISOSORBIDE MONONITRATE | 60MG; 120MG | tablet, extended release · oral | TORRENT PHARMS | Prescription | 3 Jun 2011 |
| ISOSORBIDE MONONITRATE | 120MG | tablet, extended release · oral | DEXCEL LTD | Prescription | 29 Aug 2018 |
| ISOSORBIDE MONONITRATE | 30MG; 60MG; 120MG | tablet, extended release · oral | RICONPHARMA LLC | Prescription | 5 Nov 2018 |
| ISOSORBIDE DINITRATE | 5MG; 10MG; 20MG; 30MG; 40MG | tablet · oral | ZYDUS LIFESCIENCES | Prescription | 20 Nov 2019 |
| ISOSORBIDE DINITRATE | 40MG | tablet · oral | PH HEALTH | Prescription | 23 Nov 2021 |
| ISOSORBIDE MONONITRATE | 120MG; 30MG; 60MG | tablet, extended release · oral | SHANDONG | Prescription | 29 Apr 2022 |
| ISOSORBIDE DINITRATE | 5MG; 10MG; 20MG; 30MG; 40MG | tablet · oral | RUBICON RESEARCH | Prescription | 8 Jul 2022 |
| ISOSORBIDE MONONITRATE | 30MG; 60MG; 120MG | tablet, extended release · oral | AUROBINDO PHARMA | Prescription | 7 Nov 2022 |
| ISORDIL | 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 30MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | BAUSCH | Discontinued | 9 Nov 1959 |
42 more — full table
Canada Canada — marketed products (Health Canada)
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | ISOSORBIDE DINITRATE 10 MG TAB | $0.15421 | per EA | 23 Sep 2026 |
| US NADAC | ISOSORBIDE DINITRATE 20 MG TAB | $0.19894 | per EA | 23 Sep 2026 |
| US NADAC | ISOSORBIDE DINITRATE 30 MG TAB | $0.2808 | per EA | 23 Sep 2026 |
| US NADAC | ISOSORBIDE DINITRATE 40 MG TAB | $3.3103 | per EA | 23 Sep 2026 |
| US NADAC | ISOSORBIDE DINITRATE 5 MG TAB | $0.17675 | per EA | 23 Sep 2026 |
| US NADAC | ISOSORBIDE MONONIT 10 MG TAB | $2.40398 | per EA | 30 Sep 2026 |
| US NADAC | ISOSORBIDE MONONIT 20 MG TAB | $2.29118 | per EA | 30 Sep 2026 |
| US NADAC | ISOSORBIDE MONONIT ER 120 MG | $0.16621 | per EA | 23 Sep 2026 |
| US NADAC | ISOSORBIDE MONONIT ER 30 MG TB | $0.06877 | per EA | 23 Sep 2026 |
| US NADAC | ISOSORBIDE MONONIT ER 60 MG TB | $0.09688 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Isosorbide dinitrate 10mg tablets | £11.70 | 56 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Isosorbide dinitrate 20mg modified-release tablets | £3.04 | 60 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Isosorbide dinitrate 20mg tablets | £12.15 | 56 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Isosorbide mononitrate 10mg tablets | £1.78 | 56 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Isosorbide mononitrate 20mg tablets | £3.19 | 56 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Isosorbide mononitrate 25mg modified-release capsules | £5.79 | 28 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Isosorbide mononitrate 25mg modified-release tablets | £6.75 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Isosorbide mononitrate 30mg modified-release tablets | £9.19 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Isosorbide mononitrate 30mg tablets | £7.89 | 56 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Isosorbide mononitrate 40mg modified-release capsules | £6.52 | 28 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Isosorbide mononitrate 40mg modified-release tablets | £9.14 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Isosorbide mononitrate 40mg tablets | £5.42 | 56 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 12.1. Antianginal medicines · core
Angina pectoris
Oral > Solid: 5 mg sublingual tablet
Safety signals and safety-related labeling changes
- US FDA 12 Mar 2019 BIDIL — safety-related labeling change
Labeling sections changed: Contraindications; Drug Interactions; Use in Specific Populations
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.